Objective Recent meta-analyses of antidepressant clinical trials have suggested that up to 82 % of response can be attributed to non-medication-related factors. The present study examines psychiatrists' attitudes regarding non-pharmacologic factors within the context of antidepressant pharmacotherapy. Methods A web-based, 20-question cross-sectional survey was distributed to 101 staff psychiatrists and 48 post-graduate trainees in psychiatry at an academic hospital in Boston, MA. Demographics, practice characteristics, beliefs about non-pharmacologic factors affecting prescribing practices, perceived response and remission rates, and opinions about the need for further investigations in the psychopharmacology process were assessed. Results Overall completion rate was 53 %. The final sample included 79 responses. The medians for clinician-perceived response rates (54 %) and remission rates (33 %) were in agreement with published rates. The reported median of the what portion of clinical outcomes is believed to be due to placebo effects (26 %) was numerically lower than suggested by literature. The contribution of the active ingredients of medications was perceived to be significantly higher than the contribution of patient characteristics and clinician characteristics. A longer time since graduation from medical school was significantly associated with higher belief in the effect of the active ingredients of antidepressant medications and with less perceived importance of placebo effects.
Affecting 298 million individuals worldwide, major depression remains a leading cause of years lived in disability [1] . Antidepressant medications are widely prescribed but only moderately effective for the majority of patients [2] . The limitations of current antidepressant pharmacotherapies highlight the urgent public health need for further outcome-enhancing and cost-effective interventions.
While some individual antidepressant studies show placebo effects contributing as little as 32 % toward antidepressant response [3] , published meta-analyses suggest that placebo effects account for at least twice that amount [4] . Further, in meta-analyses that minimize the effects of publication bias by reviewing only clinical trials in the FDA database, it appears that 76-82 % of antidepressant response can be attributed to non-pharmacological factors [5, 6] .
For the purposes of this paper, we broadly define placebo effects as any non-pharmacologic or non-specific factor in relation to a medication that contributes to a positive outcome. While there is still much to learn about psychosocial factors that shape antidepressant outcomes, researchers have demonstrated that non-specific factors such as the degree of involvement of patient in decision-making [7, 8] , physician communication [9, 10] , therapeutic alliance [11, 12] , patient expectations [13] [14] [15] [16] , patient preferences [17, 18] , and contact frequency [19] affect antidepressant outcomes. Furthermore, a reanalysis of data from the randomized, placebo-controlled, multicenter Treatment of Depression Collaborative Research Program study demonstrated that psychiatrists contributed more to variance in depression outcomes than active medication, suggesting that effective psychiatrists can powerfully augment the effects of the active ingredients of antidepressant medications [20] . Authors of a recent survey study of 1781 N e w Z e a l a n d a d u l t s , d e s i g n e d t o e x p l o r e t h e non-pharmacologic correlates of the perceived effectiveness of antidepressants, reported that perceived efficacy was strongly associated with patients' causal beliefs and relationship with their prescriber independent of self-reported side effects and depression severity [21] .
There has been a recent revived interest in placebo response within the scientific community, especially within psychiatry [22] . However, much of the published work has focused on neurobiological mechanisms with less attention given to psychological mechanisms. While we now understand that placebo responses produce measurable changes in brain activity that overlap with medication-induced improvement [23] , it remains unclear how these elucidated neurobiological mechanisms can be exploited to develop accessible tools for practitioners looking to leverage placebo responses in their patients.
A series of cross-sectional surveys have demonstrated that a large portion of physicians including psychiatrists prescribe impure placebos, defined as substances with physiologic effects, but which are not known to directly affect the condition being treated [24, 25] . Psychiatrists are more likely than non-psychiatrists to believe that placebos offer clinical effects [26] . However, prescribing placebos remains controversial and can be ethically problematic [27] . Alternatively, it seems prudent to optimize non-specific factors underlying placebo response when prescribing evidenced-based antidepressants [28] .
No previous studies have explored psychiatrists' attitudes about the role of these non-specific factors in psychopharmacology. For these reasons, we aimed to assess the beliefs and attitudes of psychiatry staff and residents toward these non-specific effects. In this exploratory-survey pilot study, the authors did not make any specific hypothesis prior to data collection. A greater understanding of the non-pharmacologic variables involved in antidepressant response may lead to improved outcomes through enhancement of these factors by prescribers.
Methods
Using departmental email distribution lists, we distributed a cross-sectional, web-based survey (Qualtrics, Provo, UT) among the 101 staff psychiatrists and 48 psychiatry post-graduate trainees affiliated with the psychiatry department of Harvard Medical School in Boston, MA. Eligible participants were post-graduate trainees in years 2-6 in a psychiatry program accredited by the Accreditation Council for Graduate Medical Education and staff psychiatrists with outpatient clinical activities. Trainees in the first post-graduate year were ineligible due to lack of experience in prescribing antidepressants. Other trainees were also in-eligible, if they were not prescribing standard antidepressants. This study was approved by the institutional review board at Brigham and Women's Hospital. Informed consent was received from all respondents. Original data were collected between July and August 2014.
We developed a 20-item survey (available to readers upon request), which participants completed in approximately 7 min. It included participant demographics, practice characteristics, beliefs about factors affecting prescribing practices, and opinions about the need for further investigations in the psychopharmacology process. The number of responses to each question varied, as not all participants responded to all questions. To assess prescribers' perceptions about response and remission rates for their own patient panels, we asked two separate questions with responses in 10 % increments (0-10, 11-20…91-100 %). Definitions for response and remission were provided within the prompts. In a separate question, respondents were asked to quantify their perception of what percent of antidepressant response is due to placebo effects versus active ingredients of antidepressants; possible responses also ranged from 0-10 to 91-100 % in 10 % increments. Prescribers were further asked about how much time they spent discussing risks and benefits prior to recommending initiation of treatment with an antidepressant. Answer choices were in 5-min increments ranging from 0 to 5 min to greater than 31 min. A similar question was asked inquiring the length of routine prescribers' routine psychopharmacology follow-up visits for patients with depression. Respondents were asked if their prescribing practices had changed based on the recent meta-analyses questioning the clinically relevant efficacy of antidepressants. Of those who responded yes, a follow-up question asked whether they increased or decreased their likelihood to prescribe antidepressants.
In the second part of our survey, we asked providers to quantify their beliefs about relative contributions of the following factors on treatment outcomes: therapeutic alliance, active ingredients of antidepressants, patient characteristics, and clinician characteristics [22, 28] . Total contributions were required to equal 100 %. To gain perceptions about individual patient factors (expectations of treatment, treatment preferences, ambivalence about medications, readiness to change) and clinician factors (attitude of prescriber, prescriber communication style, involvement of patient in decision-making, instillation of hope, and contact frequency), two subsequent questions were asked in the same format. The final three questions of the survey asked prescribers their opinions on the clinical relevance of placebo effects on a five-point Likert scale (strongly agree, agree, neutral, disagree, strongly disagree).
Because the overall percentage of missing values was <10 %, we did not impute missing values. Absolute and relative frequencies were used to display the distribution of categorical data, and the median was used to describe the central tendency of ordinal variables. Medians for grouped data were computed using linear interpolation [29] . Mean and standard deviation were used to describe the distribution of parametric variables. Correlations between variables were tested using Spearman's correlation coefficient, since the majority of the variables were of ordinal data. Differences in perceptions among the relative contributions of general factors, clinician factors, and patient factors were tested using within-subjects ANOVA. Significant main effects were followed up with post hoc t tests between the individual factors of each category applying Bonferroni correction for multiple testing. All analyses were carried out using SPSS 22.
Results
Ninety-three surveys were returned for an overall response rate of 62 % (77 % for trainees and 55 % for staff psychiatrists). The survey completion rate was 53 %. A total of 13 subjects were removed from the analyses because they only submitted responses for demographical data, and 1 subject was removed because his responses indicated an invalid response pattern (the most extreme answer on every question). The final sample contained n = 79 subjects. Demographicand work-related characteristics of participating psychiatrists can be found in Table 1 . Notably, the sample consists of an even distribution of male and female psychiatrists. Further, there is a broad distribution along different career stages. Only a few participants were not primarily working at an academic medical center. Median length of routine psychopharmacological visits was 26-30 min, median time spent discussing risks and benefits was 6-10 min, and median visit frequency for acutely depressed patients was every 2 weeks.
Beliefs about personal response and remission rates as well as psychiatrists' beliefs about what portion of treatment outcome can be attributed to placebo effects can be found in Table 2 . The medians for perceived response rates and remission rates were 54 and 33 %, respectively. However, the median portion of clinical outcomes attributed to placebo effects was 26 %. While 96.2 % of respondents reported familiarity with the recent literature questioning the efficacy of antidepressant medication, only 23.1 % stated that these writings have influenced their prescribing practices. Among those reported changing their prescribing practice, 80.0 % decreased their antidepressant prescriptions. Further, 96 % of the sample agreed or strongly agreed that enhancing therapeutic components that contribute to placebo responsivity may be a clinically appropriate way of improving clinical outcomes and 93 % agree or strongly agree that placebo effects in antidepressant treatment are worthy of scientific investigation, as it has the potential to illuminate the pathophysiology of depression. Psychiatrists' beliefs of the relative contributions of general factors affecting pharmacotherapy outcomes and perceptions of patient-related and clinician-related factors can be seen in Table 3 . There was a significant main effect showing that the perceived contribution of general treatment factors was not equal among each other (F 3,73 = 29.69, p < 0.001). The contribution of the active ingredients of medications was perceived to be significantly higher than the contribution of patient characteristics (t = 3.73; df = 75, p < 0.001) and clinician characteristics (t = 8.70; df = 75, p < 0.001). Further, the contribution of therapeutic alliance was perceived to be significantly higher than the contribution of patient characteristics (t = 2.91; df = 75, p = 0.030) and clinician characteristics (t = 8.99; df = 75, p < 0.001). Lastly, patient characteristics' contribution was perceived significantly higher than clinician characteristics (t = 7.02; df = 75, p < 0.001). There was no significant difference among the other possible combinations.
Among patient-related factors, there was a significant difference in the perceived relative contribution to treatment outcome (F 3,71 = 29.69, p < 0.001). The relative importance of patients' expectations was perceived as significantly more important than inquiry of patient's treatment preferences (t = 4.43; df = 73, p < 0.001) and significantly more important than the assessment of patients' ambivalence toward medication (t = 3.71; df = 73, p = 0.002). Readiness to change was felt to be significantly less relevant to outcomes than patients' treatment preferences (t = 2.71; df = 73, p = 0.048) and ambivalence toward medication (t = 2.73; df = 73, p = 0.048). There was no significant difference among the other possible combinations. Additionally, there was no significant difference among the relative contributions of the clinician-related factors (F 4,71 = 2.35, p = 0.068).
Associations between practice characteristics and psychiatrists' perceptions can be seen in Table 4 . A longer time since graduation from medical school was significantly associated with higher perceived response and remission rates and a higher belief in the effect of the active ingredients of antidepressant medications. It was further inversely related to the perceived importance of placebo effects and patient characteristics in antidepressant treatment. Among the level of trainees, a similar pattern was observed. Higher trainee level (post-graduate year (PGY)) was significantly associated with higher perceived response rate (r = 0.431, p = 0.040) and higher perceived importance of active pharmacological ingredients (r = 0.498, p = 0.018). Higher PGY was related to less perceived importance in the instillation of hope (r = 0.469, p = 0.028). Further, length of routine visits was significantly associated with lower perceived importance of patient and clinician characteristics. Longer time discussing risks and benefits of antidepressants was associated with lower perceived importance of patient characteristics. There were no significant differences among male and female respondents. Finally, higher reported response and remission rates were significantly associated with less frequent follow-up visits.
Discussion
Our findings demonstrate that psychiatric residents and attendings at a Harvard-affiliated program underestimate the impact of placebo effects on clinical outcomes for patients [4, 6, 30] , respondents reported their belief that only 26 % of clinical antidepressant response is due to non-pharmacologic or placebo effects. Differences in operational definitions of "placebo effects" may account for some of the variance. Respondents may have considered data from naturalistic, wait-list control studies suggesting that approximately 25 to 33 % of improvement occurring with medication treatment in clinical trials can also be seen in wait-list control conditions due to spontaneous remission, natural waxing and waning of symptoms, and regression to the mean [31, 32] . Other factors such as cognitive dissonance and effects of antidepressant marketing may also contribute to psychiatric bias in assessing the impact of placebo effects on antidepressant outcome. Among general factors affecting pharmacotherapy outcomes, subjects attributed more importance on the relative contribution of the active ingredients of medications in comparison to patient characteristics and clinician characteristics. This finding further highlights the weight that clinicians place on intrinsic antidepressant efficacy, sometimes at the expense of other interactional and expectancy-based factors. In contrast, Read and colleagues found that statistically significant greater number of patients who believed that the effect of antidepressants was over 50 % "chemical" in nature reported perceived depression reduction than those who believed that their effect was largely due to "placebo" effects [21] .
These findings raise several questions about how the interaction of both clinician and patient beliefs may influence outcomes.
Clinical experience, measured by years since medical school graduation, was interestingly associated with a relative devaluation of psychosocial factors affecting medication outcomes. A similar pattern was seen among trainee level. Furthermore, our data suggests that while a majority of psychiatrists may be familiar with the extant literature on placebo effects, their theoretical conceptualization of a model of placebo effects may be less agreed upon. In fact, their interpretation of available literature may have led to decreased personal belief in efficacy of antidepressants, as evidenced by decrease in prescribing in a subgroup of respondents, rather than an increased appreciation and belief in personal efficacy as a provider to enhance treatment benefits through systematic exploitation of placebo effects [33] . If corroborated in future studies with larger, more representative sample, this may represent a focus for continuing medical education programs.
While passive approaches to training physicians (e.g., workshops, manuals) may increase provider knowledge, evidence reveals that they do not consistently lead to behavioral changes in providers [34] . Research in innovative teaching methods may be necessary to promote the implementation of empirically supported treatment strategies such as fostering empathic relationships [35] , enhancing expectations of treatment benefits [36] , and managing expectations about side effects [37] . Enhancing awareness of these non-pharmacologic factors among antidepressant prescribers may represent one strategy for improving outcomes for available treatments for major depressive disorder at a time when the pipeline for novel antidepressants is relatively small [38] . Systematic psychopharmacology process investigations may impart opportunities to translate the psychological components of placebo response into concrete clinical interventions (e.g., how best to communicate expectations to patients in ways that support therapeutic efficacy, without deception). Our findings must be interpreted in the context of the limitations of our study. Our survey was conducted with a relatively small convenience sample composing of psychiatrists at an academic medical center and may not be representative of the general population of antidepressant prescribers, of which the majority composes of primary care physicians. Our sample, however, did include an even distribution of men and women at a broad distribution of stages in their careers, and perceived response and remission rates matched that of extant literature [22, 39] . Prior studies have demonstrated that psychiatrists seem to better value the influence of placebo effects in comparison to physicians in other specialties [26] . Our sample was from a single academic center in a region within the USA, which is not representative of regional and philosophical variation in prescribing practices [40] . In addition, while the majority of psychiatrists practice within the community, our sample consisted of academic physicians. We were unable to find previous studies reporting the variation in prescribing patterns between academic and community psychiatrists, limiting our ability to explore external validity. Future questionnaire studies could include primary care providers, community psychiatrists, and an academic comparator group from a different geographical region. Because of our small sample size, we recognize that we may have not had power to detect other factors with small effects on beliefs about treatment effects. We cannot be certain of how survey respondents differed from non-respondents or the degree to which response bias may have influenced our reported findings. Finally, we do not know the degree to which respondents' responses on the relative importance of contextual factors reflect their actual decision-making and behaviors in the clinical setting.
The underappreciation of the importance of placebo effects represents a significant gap in awareness among antidepressant prescribers. To the extent that academic psychiatrists are not attending to and making use of available evidence regarding psychosocial factors in the prescribing process that promote positive pharmacologic outcomes, they cannot be said to be practicing evidence-based prescribing. Educating prescribers about the evidence based on psychosocial mediators of placebo effects is an important and economically favorable strategy for improving clinical outcomes. Further investigations in psychopharmacology research exploring psychological processes associated with clinical improvement are warranted.
Implications for Educators
• An underappreciation of the importance of placebo effects among academic antidepressant prescribers represents an important education opportunity, especially among more experienced academic psychiatrists.
• Non-pharmacological effects of antidepressant treatment clearly influence outcomes in depression.
• Clinical experience was associated with relative devaluation of nonpharmacologic effects in relation to medication effects in antidepressant pharmacotherapy.
• By increasing our understanding of the non-pharmacologic factors, we may be better able to identify and enhance those factors which lead to better outcomes for patients for whom we prescribe antidepressants.
• Further investigations in psychopharmacology research exploring psychological processes associated with clinical improvement are warranted.
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